Baird Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $8
Portfolio Pulse from jenniferd'souza@benzinga.com
Baird analyst Jack Allen has maintained an 'Outperform' rating on Taysha Gene Therapies (NASDAQ:TSHA) and raised the price target from $6 to $8.
August 15, 2023 | 12:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst has maintained an 'Outperform' rating on Taysha Gene Therapies and raised the price target from $6 to $8.
The news is directly related to Taysha Gene Therapies. The 'Outperform' rating and raised price target by Baird analyst Jack Allen indicates a positive outlook for the company, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100